.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Novartis
US Department of Justice
Mallinckrodt
Medtronic
Covington
Chubb
McKinsey
Cerilliant
Moodys

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,821,975

« Back to Dashboard

Which drugs does patent 6,821,975 protect, and when does it expire?


Patent 6,821,975 protects ADCIRCA and CIALIS and is included in two NDAs. There have been zero Paragraph IV challenges on Adcirca and Cialis

This patent has thirty-eight patent family members in thirty-two countries.

Summary for Patent: 6,821,975

Title: Beta-carboline drug products
Abstract:A compound of structural formula (I), and pharmaceutically acceptable salts and solvates thereof, wherein the compound is in free drug particulate form, is disclosed.
Inventor(s): Anderson; Neil R. (West Lafayette, IN), Hartauer; Kerry J. (Carmel, IN), Kral; Martha A. (Indianapolis, IN), Stephenson; Gregory A. (Fishers, IN)
Assignee: Lilly ICOS LLC (Wilmington, DE)
Application Number:10/031,463
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Use; Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly CoADCIRCAtadalafilTABLET;ORAL022332-001May 22, 2009RXYesYes► Subscribe► SubscribeYY► Subscribe
LillyCIALIStadalafilTABLET;ORAL021368-004Jan 7, 2008RXYesNo► Subscribe► SubscribeYYERECTILE DYSFUNCTION► Subscribe
LillyCIALIStadalafilTABLET;ORAL021368-004Jan 7, 2008RXYesNo► Subscribe► SubscribeYYTREATMENT OF SEXUAL DYSFUNCTION► Subscribe
LillyCIALIStadalafilTABLET;ORAL021368-001Nov 21, 2003RXYesNo► Subscribe► SubscribeYYTREATMENT OF SEXUAL DYSFUNCTION► Subscribe
LillyCIALIStadalafilTABLET;ORAL021368-001Nov 21, 2003RXYesNo► Subscribe► SubscribeYYERECTILE DYSFUNCTION► Subscribe
LillyCIALIStadalafilTABLET;ORAL021368-001Nov 21, 2003RXYesNo► Subscribe► SubscribeYYTREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA► Subscribe
LillyCIALIStadalafilTABLET;ORAL021368-002Nov 21, 2003RXYesNo► Subscribe► SubscribeYYTREATMENT OF SEXUAL DYSFUNCTION► Subscribe
LillyCIALIStadalafilTABLET;ORAL021368-002Nov 21, 2003RXYesNo► Subscribe► SubscribeYYERECTILE DYSFUNCTION► Subscribe
LillyCIALIStadalafilTABLET;ORAL021368-003Nov 21, 2003RXYesYes► Subscribe► SubscribeYYTREATMENT OF SEXUAL DYSFUNCTION► Subscribe
LillyCIALIStadalafilTABLET;ORAL021368-003Nov 21, 2003RXYesYes► Subscribe► SubscribeYYERECTILE DYSFUNCTION► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,821,975

PCT Information
PCT FiledAugust 01, 2000PCT Application Number:PCT/US00/20981
PCT Publication Date:February 08, 2001PCT Publication Number: WO01/08688

International Patent Family for Patent: 6,821,975

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1200092► Subscribe
Poland199469► Subscribe
Poland353268► Subscribe
Peru04802001► Subscribe
New Zealand516613► Subscribe
Norway321602► Subscribe
Norway20020531► Subscribe
MexicoPA02001197► Subscribe
Japan4456788► Subscribe
Japan2003505510► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Julphar
QuintilesIMS
Dow
Medtronic
Queensland Health
Express Scripts
Cerilliant
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot